

SUBJECT INDEX—VOLUME 6, 2002

- Adenocarcinoma
AGUS, age and cell type effects on patient management, 92
AGUS favor neoplasia, occult adnexal malignancy, 1
Adenomyoma, polypoid, mimicking cervical adenocarcinoma, 33
Adherence to care, follow up for colposcopy, 17
Adnexal malignancy, occult, AGUS favor neoplasia, 1
AGUS
age and cell type effects, patient management, 92
atypical polypoid adenomyoma or cervical cancer, 33
favor neoplasia, occult adnexal malignancy, 1
Antifungal agents, oral *versus* intravaginal, treatment of vulvovaginal candidiasis (Thrush), 203(ab)
ASCCP President's Report, 57
Atypical glandular cells
premenopausal *versus* postmenopausal population, 185(ab)
undetermined significance, community hospital setting, 186(ab)
- Biopsy
cervical
SpiraBrush CX for transepithelial tissue sampling, 187(ab)
topographical distribution in lesions, 177(ab)
excisional
CIN 1,2, 80
colposcopically directed, diagnosis of dysplasia, 178(ab)
laser cone, negative, investigations of, 84
Book reviews
Atlas of Vulvoscopic Nomenclature, 63
Pelvic Pain Diagnosis and Management, 124
Breast cancer, community-based screening, underserved women, 204(ab)
- Cancer screening
community-based, underserved women, 204(ab)
personal health record booklets, 257(ab)
public health clinics, 204(ab)
Carcinoma in-situ, cervical squamous cell, intraepithelial involvement of endometrium, 184(ab)
 β -Carotene, serum and tissue levels, regression of CIN and, 220
Cervical cancer
ASCUS Pap smear, in pregnancy, 116
atypical polypoid adenomyoma mimicking, 33
c-myc-induced amplification of *DHFR* gene, 167(ab)
detection prototype device, human factors evaluation of, 188(ab)
invasive, in sexual workers, 76
prevention knowledge, health behaviors and, multiethnic cohort of women, 259(ab)
prognostic marker, antibodies to HPV 16 L1 virus-like particles, 258(ab)
reproductive-age women at high risk, Pap test usage in, 258(ab)
risks, negative screening cytology and, 169(ab), 170(ab)
screening
detection rate of HPV and, 172(ab)
\$10 incentive to improve follow-up, 187(ab)
tampon sampling, 174(ab)
weekly repeated type-specificity H/V testing and, 172(ab)
self-collected samples for HPV detection, 259(ab)
social and cultural barriers to Pap smears, urban population, 173(ab)
Cervical cone margins, negative, microcolposcopy and, 5
Cervical cytologic abnormalities, 2001 Consensus Guidelines, 127
Cervical dysplasia
colposcopic diagnosis, colposcopically directed biopsy *versus*, 188(ab)
imiquimod application in, cytokine activation after, 179(ab)
postpartum evolution of lesions, route of delivery effects, 212
practice patterns, rural state, 180(ab)
recrudescence, women with HIV, 259(ab)
Cervical endometriosis, cytology in cervical smear, 162
Cervical hyperplasia, AGUS, age and cell type effects on patient management, 92
Cervical intraepithelial neoplasia (CIN)
aberrant E-cadherin expression in, with false-negative Pap smear, 175(ab)
AGUS Pap smear, community hospital setting, 186(ab)
colposcopically directed biopsies, CIN 1,2, 80
colposcopic biopsy showing CIN2, 23
colposcopy, colposcopically directed biopsy *versus*, 188(ab)
comparison of management strategies, 176(ab)
toposcopically directed biopsies, diagnosis of dysplasia, 178(ab)
cytologic evaluation, after loop excision, 27
efficacy data *versus* patient safety, 206
high-grade squamous, HIV-positive and -negative women, 182(ab)
HPV relations, atypical pap smear patients, 168(1b)
incomplete excision of disease, microcolposcopy and, 5
Pap smear and HPV testing, former Soviet Union, 97
practical prototype optical detection device, 174(ab)
regression, serum and tissue micronutrient levels and, 220
in sexual workers, 76

- topographical distribution in, enrollment colposcopic exam results, 177(ab)
 treatment options, 247
 in women with HIV, HAART use, 111
- Cervical neoplasm, detection with HPV oligonucleotide microarray, 171(ab)
- Cervical squamous intraepithelial lesions
 AGUS, age and cell type effects, patient management, 92
 HPV typing in, 61(ab)
 low-grade, adolescent, 244
 postpartum evolution, route of delivery effects, 212
- Cervicography, triage in mildly abnormal cervical cytology results, 203(ab)
- Cervix, sclerosing lipogranuloma, 218
- Circumcision, male, HPV infection and cervical cancer in female partners, 256(ab)
- Clinical trials
 CIN, efficacy *versus* patient safety, 206
 colposcopy quality control for, 11
- Colposcopy
 biopsy, showing CIN2, 23
 cervical squamous intraepithelial lesions, postpartum evolution of, 212
 cytology and, findings in abnormal vaginal flora, 155
 diagnosis, colposcopically directed biopsy *versus*, cervical dysplasia, 188(ab)
 enrollment exams, topographical distribution of cervical neoplasia, 177(ab)
 follow up for, knowledge, anxiety and fear effects, 17
 mimics of glandular disorders, 53
 nosocomial infections, transmitted by Monsel's, 228
 quality control, clinical trials, 11
 teleconsultation in, 177(ab)
 unsatisfactory, CIN patients, microcolposcopy and, 5
- Complications, hysteroscopic, 39
- Computer, telecolposcopy based on
 compared with network colposcopy, 178(ab)
 qualitative assessment, 145
- Condoms, carrying *versus* use of, minority adolescent females, 62(ab)
- Condylomata acuminata, vulvar, perianal, and perineal, staging of, Mexican population, 189(ab)
- Conization, negative margins, microcolposcopy and, 5
- Contigen, Durasphere and, long-term follow-up in stress urinary incontinence, 239
- Cost effectiveness, loop excision, cytology for evaluation of endocervical canal after, 27
- Cytobrush, endocervical canal, replacement of curette, 171(ab)
- Cytokines, activation, after imiquimod application in cervical dysplasia, 179(ab)
- Cytology
 cervical
 computerized karyometric analysis for, 173(ab)
 identification of noncervical neoplasms, 184(ab)
 mildly abnormal results, cervicography for, 203(ab)
 Pap test specimen adequacy and quality, 195
 colposcopy and, findings in abnormal vaginal flora, 155
 endometriosis, 162
 evaluation of endocervical canal, after loop excision, 27
 liquid-based, Pap smear comparison in pregnancy, 175(ab)
 liquid-based preparations, cervical screening techniques, 183(ab)
 Pap smear, HPV testing and, former Soviet Union, 97
 screening, negative, risk of cervical cancer in prepaid health plan, 169(ab), 170(ab)
- Dihydrofolate reductase* gene, c-myc-induced amplification, cervical neoplasia, 167(ab)
- Durasphere, Contigen and, long-term follow-up in stress urinary incontinence, 239
- E-cadherin, aberrant expressions, cervical intraepithelial neoplasia, 175(ab)
- Education, brief, intensive intervention, colposcopy quality control and, 11
- Endocervical curettage, loop excision, cytologic examination after, 27
- Endocervix, specimens, cytobrush and curette comparison, 171(ab)
- Endometrial cells, shedding of, cytology of cervical endometriosis and, 162
- Endometrial hyperplasia, AGUS, age and cell type effects on patient management, 92
- Endometriosis, cytology of, cervical smear, 162
- Endometrium, intraepithelial involvement of, cervical carcinoma in-situ, 184(ab)
- False negative reporting, laser cone biopsy, 84
- Glandular disease, differentiating from colposcopic mimics, 53
- Health records, personal booklet, cancer screening behavior and, 257(ab)
- Heterocopulative syndrome, 257(ab)
- Highly active antiretroviral therapy (HAART), CIN, effects on HIV-positive women, 111
- Histology, colposcopic biopsy, CIN2, 23
- Human Immunodeficiency virus (HIV)
 cervical dysplasia and, recrudescence, 259(ab)
 CIN in, HAART use, 111
- Human papillomavirus (HPV)
 cervical intraepithelial neoplasia relations
 atypical pap smears, 168(ab)
 urban colposcopy clinic, 180(ab)
 detection rate, factors in, 172(ab)
 oligonucleotide microarray, detection of cervical cancer, 171(ab)

- Pap test screening and prevalence of, women who have sex with women, 61(ab)
 polymerase chain reaction detection of, 259(ab)
 testing
 abnormal Pap smear, 181(ab)
 management strategies for CIN 1 or less, 176(ab)
- Human papillomavirus-16 E6 variants, cervical squamous intraepithelial lesions, 61(ab)
- Human papillomavirus 16 L1, virus-like particles, antibodies to, cervical cancer, 258(ab)
- Hysteroscopy, complications, 39
- Image analysis, computerized karyometric, identification of cervical disease, 173(ab)
- Imiquimod, cervical application, cytokine activation after, 179(ab)
- Immunocompetence, use of HAART and, CIN, 111
- Infection, nosocomial, Monsel's solution in transmission of, 179(ab), 228
- Injectable bulking agent, treatment of stress urinary incontinence, 239
- In Memoriam, Winston Holbrook Weese, M.D., 125
- Ipsilateral lymphadenectomy, for vulvar cancer, 150
- Laparotomy, AGUS favor neoplasia, occult adnexal malignancy, 1
- Laser surgery, loop surgical excision or, treatment of VIN, 232
- Lipogranuloma, sclerosing, cervix, 218
- Loop surgical excision, treatment of VIN, 232
- Macrophages, squamous cell carcinoma of the cervix, 170(ab)
- Mammography, HMO women overdue for, screening, 204(ab)
- Metastatic lesions, noncervical, detection with cervical cytology, 184(ab)
- Microcolposcopy, protection from incomplete excision of disease, CIN patients, 5
- Mixed Mullerian tumor, atypical polypoid adenomyoma, 33
- Monsel's solution
 history of, 225
 transmission of nosocomial infections and, 179(ab), 228
- Mucosal immunity, HIV-negative and -positive women, cervical intraepithelial lesions, 182(ab)
- Pap smear
 abnormal
 benign and inflammatory vaginal lesions, 120
 \$10 incentive to improve follow-up, 187(ab)
 management, ASCCP 2000 Biennial meeting participants, 181(ab)
 83-year-old woman, management of, 49
 ASCUS, in pregnancy, 116
 atypical glandular cells, premenopausal *versus* postmenopausal population, 185(ab)
 conventional, liquid-based cytology and, comparison in pregnancy, 175(ab)
 conventional cytology, HPV testing and, cervical cancer, former Soviet Union, 97
 false-negative, aberrant E-cadherin expression in cervical intraepithelial neoplasia, 175(ab)
 fluid-based cytologies superior to, 258(ab)
 HMO women overdue for, screening, 204(ab)
 practical prototype optical detection device or, for cervical neoplasia, 174(ab)
 prevalence of human papillomavirus and, women who have sex with women, 61(ab)
 reproductive-age women at high risk, 258(ab)
 social and cultural barriers, urban population, 173(ab)
 specimen adequacy, quality indicators and, ASCCP Patient Management Guidelines, 195
- Patient education, HPV and cervical neoplasia, urban colposcopy clinic, 180(ab)
- Patient safety, clinical trials in CIN, 206
- Postcoital bleeding, evaluation, 256(ab)
- Practice patterns
 abnormal Pap smear, management, ASCCP 2000 Biennial meeting participants, 181(ab)
 cervical cancer, in a rural state, 180(ab)
- Pregnancy
 ASCUS Pap smears in, 116
 cervical squamous intraepithelial lesions, postpartum evolution of, 212
 endocervical cell recovery, conventional Pap smear and liquid-based cytology in, 175(ab)
- Presidential Column, The health and status of the Society, 73
- Pruritus vulvae, contact sensitivity in, 202(ab)
- Quality control, colposcopy, clinical trials, 11
- Receiver operating characteristics curve, Pap smear and HPV testing, former Soviet Union, 97
- Retinol, serum and tissue levels, regression of CIN and, 220
- Sexually transmitted diseases, prevalence of, condom carrying and use in minority adolescent females, 23(ab)
- Sexual workers, preinvasive and invasive lesions of the cervix in, 76
- Society News, 2002 IFCPC World Congress, 254
- Spectroscopy, cervical cancer detection prototype device, human factors evaluation of, 188(ab)
- Spira-Brush, sampling
 transepithelial cervical tissue, 187(ab)
 uterine ectocervix, 185(ab)
- Squamous cell carcinoma, cervical, macrophages in, 170(ab)
- Stress urinary incontinence, Durasphere or Contigen treatment, long-term follow-up, 239
- Surgery, wide local excision, for vulvar cancer, 150, 167(ab)

- Tampons, self-sampling, high-risk HPV, 174(ab)
- Telecolposcopy
 - computer-based and network, comparison, 178(ab)
 - network, computer-based, comparison, 178(ab)
- Teleconsultation, efficacy in colposcopy, 177(ab)
- Telemedicine network, qualitative assessment, 145
- Test characteristics
 - HPV, weekly repeated type-specificity, 172(ab)
 - HPV detection rate, cervical cancer screening and, 172(ab)

- Urban health, social and cultural barriers to Pap smears, 173(ab)
- Uterine ectocervix, sampling, spiral shaped brush use in, 185(ab)

- Vaginal flora
 - abnormal, colposcopic and cytologic findings, 155
 - bacterial vaginosis and, women who have sex with women, 257(ab)
 - with vulvar pain, behavioral and clinical findings, 202(ab)
- Vaginal intraepithelial neoplasm, treatment with upper vaginectomy, 183(ab)

- Vaginal lesions, benign and inflammatory, abnormal Pap smear and, 120
- Vaginectomy, upper, treatment of vaginal intraepithelial neoplasia, 183(ab)
- Vaginosis, bacterial, vaginal flora and, women who have sex with women, 257(ab)
- Vitamin E, serum and tissue levels, regression of CIN and, 220
- Vulvar cancer
 - early, ipsilateral superficial inguinal lymphadenectomy for, 150
 - intraepithelial neoplasm, posttherapeutic management, 167(ab)
- Vulvar intraepithelial neoplasia (VIN)
 - loop electrosurgical excision procedure, 232
 - posttherapeutic management, 167(ab)
- Vulvar pain, vaginal flora and, behavioral and clinical findings, 202(ab)
- Vulvar vestibulitis, methylprednisolone and lidocaine treatment, 62(ab)
- Vulvar vestibulitis syndrome, proinflammation immune response, defective regulation of, 259(ab)
- Vulvovaginal candidiasis (Thrush), treatment, oral *versus* intra-vaginal antifungal agents, 203(ab)